Key points
• IL-21 activates IL-21R dependent singling to mediate direct cytotoxicity of mantle cell lymphoma cells.
• Indirect effects of IL-21 on immune effector cells also contribute to anti-tumor effects against mantle cell lymphoma.
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Introduction
Mantle cell lymphoma (MCL) is a morphologically distinct subtype of lymphoma that accounts for 6-8% of non-Hodgkin lymphomas (NHL). MCL is characterized by the chromosomal translocation (11;14)(q13;q32) that juxtaposes CCND1 to the immunoglobulin heavy chain (IGH) gene enhancer region 1 . This translocation leads to constitutive overexpression of cyclin D1, resulting in early expansion of neoplastic B cells in the lymphoid follicle mantle zone, contributing to increased cell proliferation.
MCL is a highly aggressive disease with a median overall survival (OS) of 3 to 5 years 2-4 .
Although treatment with conventional chemotherapy results in an overall response of 60-80%, the majority of patients relapses and succumb to MCL 5 . The addition of the anti-CD20 antibody rituximab to first line therapy led to improved complete remission rates, but did not prolong progression free and OS 6 . Consolidation with autologous stem cell transplantation improved response rates and duration, but did not result in lasting remissions 7 . Studies incorporating cytarabine (ARA-C) as part of the initial regimens led to marked increases in complete response rates and prolonged survival, yet failed to lead to cure of patients 8 . Consequently, there is an urgent need to develop newer therapeutic approaches for MCL.
Interleukin-21 (IL-21), a member of the IL-2 cytokine family, is mainly secreted by For personal use only. on April 15, 2017. by guest www.bloodjournal.org From depending on the cellular context and type of stimulus [10] [11] [12] [13] [14] . Surprisingly, unlike other γ C family members, IL-21 exhibits pro-apoptotic effects on activated and naïve B-cells 15 .
IL-21 anti-tumor activity was demonstrated in multiple preclinical studies as single agent or in combination with chemotherapy [16] [17] [18] [19] [20] [21] [22] [23] [24] and was evaluated in clinical trials for renal cell carcinoma and metastatic melanoma [24] [25] [26] . In solid tumors not expressing IL-21R, the anti-tumor effects of IL-21 are mediated via NK or/and CD8 + T-cell activation 21, 27, 28 .
We have previously demonstrated that IL-21 exerts direct cytotoxicity on IL-21R
expressing diffuse large B cell lymphoma (DLBCL) cell lines and primary tumors in-vitro and in-vivo 18 . In our study IL-21-induced cell death was mediated via STAT3 dependent cMyc upregulation, resulting in activation of the intrinsic apoptosis pathway.
In-vitro studies also demonstrated that IL-21 exerts direct cytotoxicity in chronic lymphocytic leukemias (CLL) and MCL cell lines, but via different mechanisms: caspase-8 activation leading to Bid cleavage followed by caspase-3 activation 17, 19 and STAT1 activation, respectively 22 . The distinct cellular mechanisms of IL-21-mediated cytotoxicity in different B cell tumors were unexpected and surprising. However, in the case of MCL, the report was based on in-vitro studies in only 2 cell lines. To reconcile these findings and to more carefully examine the potential role of IL-21 for MCL therapy, we analyzed the direct IL-21-mediated effects on survival, proliferation and apoptosis in a large set of MCL cell lines and primary tumors. Further, we also examined the indirect immunostimulatory effects of IL-21 signaling on NK and T cells and their contribution to its anti-tumor activity in MCL.
Materials and Methods
Reagents, antibodies, cell lines, primary tumors and in-vitro studies.
Reagents, acquisition of primary tumors and statistical methods are described in the Supplemental Materials and Methods.
MCL cell lines: Mino, HBL-2, SP-53, Jeko-1, IRM-2, G-519, L-128, Z-138 and DLBCL cell line RC-K8 were cultured in RPMI 1640 medium (Gibco BRL) supplemented with 10% heat inactivated fetal bovine serum (FBS; Mediatech), 2mM glutamine (Gibco BRL), and 100U/L penicillin/streptomycin (Gibco BRL). HeLa and 293T cells were cultured in Dulbecco modified Eagle medium (Mediatech) supplemented with 10% FBS, 2mM glutamine, and penicillin/streptomycin. The FC-muMCL1 mouse lymphoma cell line, generated from the splenocytes of a 1 year old male Eμ-cyclin D1 transgenic C57BL/6 mouse injected with pristane, was a kind gift of Dr. M.R. Smith (Cleveland Clinic, Ohio) 29 . These cells were maintained in RPMI 1640 medium supplemented with 15% FBS, 1mM non-essential amino acid, 1mM Napyruvate, 2mM glutamine, and penicillin/streptomycin.
Mice studies
To assess the in-vivo efficacy of IL-21 in a murine MCL model, four week old female C57BL/6 mice (Charles River) were subcutaneously (s.c.) inoculated with FC-muMCL1 cells (10×10 6 cells/100μl RPMI) into the right flank. All mice were housed according to institutional animal care and use committee (IACUC) guidelines in accordance with an approved protocol and monitored on a daily basis for tumor growth. Once tumor volume reached 100mm 3 , mice were divided into two experimental groups (n=5/group) and treated intratumorally with PBS (50μl) or IL-21 (10μg) twice a day in the first week and once a day for the following week.
Tumor-bearing mice were assessed every two days for weight loss and tumor volume by 
In-vivo lymphocyte subsets depletion
For in-vivo CD4, CD8 and NK cells depletion, C57BL/6 mice were treated i.v. with antimouse CD4 (GK1.5), CD8 (2.43) antibodies (BioXcell) and anti-asialo GM1 (Wako Chemicals) on days -7, -5 and 0 (where day 0 is the day of tumor inoculation). Animals treated with control
Ig with irrelevant specificity were used as non-depleted controls. The antibody injections were repeated i.v. every 6 days until the end of study. Depletion of lymphocyte subsets were confirmed by flow cytometry. Control or NK, CD4 and CD8 depleted mice were implanted with FC-muMCL1 cells and treated as described above.
Results

MCL cell lines and primary tumors express IL-21R on cell surface
Analysis of cell-surface IL-21R expression in a panel of 8 MCL cell lines demonstrated heterogeneous expression levels, with highest levels on Mino cells ( Figure 1A ). All cell lines were IL-21R positive. MCL cells isolated from primary tumors also expressed IL-21R at different levels and proportions of MCL cells (4 MCL tumors had more than 90% cells expressing IL-21R and 3 tumors had IL-21R expression in 18 to 56% of cells, Supplemental Figure S1A -B). Figure S2) . IL-21-induced cell killing plateaued at the 100ng/mL, similar to our previous study in DLBCL 18 . The 100ng/ml concentration of IL-21 was previously commonly used in multiple studies and can be achieved in patients' serum using IL-21-doses evaluated in clinical trials 17, [30] [31] [32] . Consequently, we selected 100ng/ml IL-21 dose and analyzed its cytotoxic effects in additional MCL cell lines by flowcytometry using YO-PRO and PI staining assay. Cell lines and primary tumors were defined as We next evaluated the effects of IL-21 on 7 de novo, untreated primary human MCL specimens. IL-21 induced cell death in 3 of 7 primary tumors, with all susceptible tumors expressing IL-21R in more than 90% of cells ( Figure 1C and Supplemental Figure S1A- Figure S1A -B). These findings implied that IL-21R expression is not sufficient for IL-21-induced cell death, since not every cell line and primary tumor with surface IL-21R expression exhibited cell death upon IL-21 treatment (Supplemental Figure S1C) . Noticeably, none of the normal IL-21R expressing B-cells obtained from blood or lymph nodes of healthy volunteers were killed by IL-21, suggesting specificity of cytotoxic effects to the tumor cells ( Figure 1D ). Overall, our data demonstrate a non-uniform response of MCL cell lines and primary tumors to IL-21's direct cytotoxicity. Figure S5 ). Figure 3A) . In contrast, IL-21 did not induce an increase in cMyc protein levels in resistant cell lines (Jeko-1, L-128 and G-519) and primary cells (Specimen-4), suggesting that cMyc may play a critical role in IL-21-induced cell death in MCL ( Figure 3A ).
IL-21 induces
IL-21 induced apoptosis of MCL cells is cMyc-dependent
To determine whether cMyc up-regulation is required for IL-21's apoptotic effects, we knocked down cMyc using specific siRNAs. cMyc knockdown prevented cMyc up-regulation following IL-21 treatment and blocked IL-21-induced cell death as opposed to nontargeting control siRNA (p<0.005; Figure 3B ). Figure 3C ). Overall, these data suggest that cMyc up-regulation is imperative for direct IL-21 cytotoxicity in MCL, similarly to DLBCL 18 . line Mino but not in the IL-21 resistant line Jeko-1 ( Figure 4A ). Moreover, increased Bax expression was observed in sensitive but not resistant primary tumors (Supplemental Figure S4 ).
IL-21 induces MCL apoptosis via STAT3 and Bax
These findings suggest that similarly to DLBCL, IL-21-induced cMyc up-regulation modulates expression of Bcl-2 family proteins to trigger cell death 18 .
Bax is reported to be essential for cMyc-induced apoptosis 33, 34, 36 . To demonstrate that observed changes in Bax expression might contribute to IL-21-induced apoptosis in MCL, siRNAs were used to knock-down Bax. Bax knockdown markedly decreased apoptosis after IL-21 treatment ( Figure 4B ). These findings suggest that Bax is a downstream effector of cMycinduced apoptosis, as we reported in DLBCL 18 .
We next interrogated the upstream signaling cascade mediating the IL-21-induced increase in cMyc expression. cMyc is a known target of STAT3 [37] [38] [39] , which was shown to be However, previously published data suggested that IL-21-induced apoptosis of MCL cells is mediated via STAT1 dependent signaling 22 . To interrogate the potential contribution of STAT1 to IL-21-induced apoptosis in MCL, we knocked down STAT1 using specific siRNAs.
In contrast to the previous report, complete STAT1 knockdown did not affect IL-21-induced apoptosis in the Mino cell line ( Figure 4D ). siRNA-induced STAT3 and STAT1 knockdown was specific (Supplemental Figure S5A) , excluding the possibility of concomitant knockdown of 
Baseline mitochondrial priming does not correlate with IL-21 sensitivity in MCL cell lines
To further exclude the possibility of nonspecific IL-21-induced killing, we examined baseline mitochondrial priming in IL-21 sensitive and resistant cell lines. It was previously shown that baseline cell mitochondrial priming to apoptosis may determine sensitivity of cancer cells to different cytotoxic agents 40, 41 . Mitochondrial priming is controlled by the BCL-2 family of pro-apoptotic and anti-apoptotic proteins 42, 43 . We adopted the BH3 profiling technique to determine the magnitude of response of mitochondria to peptides derived from the BH3 domains of pro-apoptotic proteins via measuring cytochrome C release. The greater the loss of cytochrome C caused by the BH3-only peptides, the cells are more primed for death. We BH3
profiled MCL cell lines to determine their priming status using different concentrations of BIM 
IL-21 induces indirect cytotoxicity through NK-cell mediated lysis
Apart from IL-21R-dependent direct cytotoxicity, IL-21-mediated immune cell activation is also known to contribute to its anti-tumor effects against a variety of cancers 21, 28, 44, 45 . To clarify the contribution of IL-21-induced immunomodulatory effects to its anti-MCL activity, we performed cell cytotoxicity assays using NK cells isolated from peripheral blood. As opposed to the direct cytotoxicity, immune-mediated effects of IL-21 are commonly induced by lower IL-21
concentrations (e.g. 10ng/mL) 45 . Consequently, human NK cells were stimulated overnight with IL-21 (10 ng/mL) or PBS. IL-21 significantly enhanced NK cell cytolytic activity against Jeko-1 ( Figure 5A ) and MCL primary tumors ( Figure 5B ), while B-cells isolated from healthy volunteers were unaffected ( Figure 5B ). Consequently, primary MCLs and MCL cell lines that are resistant to direct IL-21-mediated cytotoxicity may be sensitive to IL-21-activated NK-cell mediated cell lysis.
4
Preclinical studies have demonstrated that IL-21 augments the ADCC activity of antibody coated target cells by enhanced NK cell activation in CLL primary tumors and animal B-cell lymphoma and breast cancer models 17, 45 . However, this phenomenon was not explored in MCL tumors. To extend these findings, we tested the ability of IL-21 to enhance ADCC against MCL primary tumors coated with an anti-CD20 mAb (rituximab). IL-21-activated NK cells exhibited significantly increased rituximab-specific ADCC activity against tested primary tumors (p<0.005 and p<0.01; Figure 5C ). In contrast to animal studies, IL-21 enhanced NK but not CD4 + T cell cytolytic activity in human MCL cells line Jeko-1 ( Figure 5A and not shown). We demonstrate that IL-21 induced apoptosis of MCL cells is mediated through activation of the STAT3-cMyc pathway, leading to up-regulation of pro-apoptotic (Bax) and down-regulation of anti-apoptotic (Bcl-2 and Bcl-X L ) proteins. In agreement with our study in GAPDH and actin served as loading controls (*p < 0.05 and ***p < 0.005). For personal use only. on April 15, 2017. by guest www.bloodjournal.org From
In-vivo
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